医学と薬学　76/4　2019年4月号

出版社： 自然科学社
発行日： 2019-03-27
分野： 薬学  >  雑誌
ISSN： 03893898
雑誌名：
特集： 心臓血管疾患（II）
電子書籍版： 2019-03-27 （第1版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

2,200 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

1,320 円(税込)

購入する

目次

  • 特集　心臓血管疾患（II）

    不整脈薬（抗凝固療法）
    不整脈（抗不整脈薬）
    肺高血圧症
    大動脈疾患
    末梢動脈疾患

    研究
    　薬局・薬剤師に望む感染症へのアプローチ

    臨床研究
    　ブロナンセリン錠4mg「アメル」の生物学的同等性試験
    　ブロナンセリン散2％「アメル」の生物学的同等性試験

    Diagnosis
    　インフルエンザウイルス抗原迅速診断キット
    　　「ラピッドテスタ®FLU・NEXT」の検出感度と操作性に関する検討
    　肝炎およびレトロウイルス測定試薬8項目を用いた
    　　全自動化学発光免疫測定装置Alinity®iの日常検査への導入検討
    　Atellica Solutionを用いたCEA，AFP，CA19-9，CA125，
    　　CA15-3，PSAおよびfree PSA測定の基礎的性能評価
    　ECLIA法によるインスリン様成長因子I測定試薬
    　　（エクルーシス試薬IGF-1）の基礎性能評価

    Cosmetic
    　シュガーパック化粧品のアトピー・乾燥肌改善効果

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

【特集 心臓血管疾患 ( II ) 】

P.427 掲載の参考文献
1) Olesen JB, Torp-Pedersen C : Stroke risk in atrial fibrillation : Do we anticoagulate CHADS2 or CHA2DS2-VASc > /=1, or higher? Thromb Haemost 113 : 1165-1169, 2015.
 
2) Suzuki S, Yamashita T, Okumura K et al : Incidence of ischemic stroke in Japanese patients with atrial fibrillation not receiving anticoagulation therapy-pooled analysis of the Shinken Database, J-RHYTHM Registry, and Fushimi AF Registry. Circ J 79 : 432-438, 2015.
 
3) Kodani E, Atarashi H, Inoue H et al : Impact of Blood Pressure Control on Thromboembolism and Major Hemorrhage in Patients With Non-valvular Atrial Fibrillation : A Subanalysis of the J-RHYTHM Registry. J Am Heart Assoc 5, 2016.
 
4) Ishii M, Ogawa H, Unoki T et al : Relationship of Hypertension and Systolic Blood Pressure With the Risk of Stroke or Bleeding in Patients With Atrial Fibrillation : The Fushimi AF Registry. Am J Hypertens 30 : 1073-1082, 2017.
PubMed
5) Sadanaga T, Kohsaka S, Mitamura H et al : Elevated B-type natriuretic peptide level as a marker of subsequent thromboembolic events in patients with atrial fibrillation. Heart Vessels 26 : 530-535, 2011.
PubMed
6) O'Brien EC, Simon DN, Thomas LE et al : The ORBIT bleeding score : a simple bedside score to assess bleeding risk in atrial fibrillation. Eur Heart J 36 : 3258-3264, 2015.
 
7) Fang MC, Go AS, Chang Y et al : A new risk scheme to predict warfarin-associated hemorrhage : The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol 58 : 395-401, 2011.
 
8) Kirchhof P, Benussi S, Kotecha D et al : 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 37 : 2893-2962, 2016.
PubMed
9) Akao M, Chun YH, Esato M et al : Inappropriate use of oral anticoagulants for patients with atrial fibrillation. Circ J 78 : 2166-2172, 2014.
PubMed
10) Inoue H, Uchiyama S, Atarashi H et al : Post-marketing surveillance on the long-term use of dabigatran in Japanese patients with nonvalvular atrial fibrillation : Preliminary report of the J-dabigatran surveillance. J Arrhythm 32 : 145-150, 2016.
 
11) Ogawa S, Ikeda T, Kitazono T et al : Present profiles of novel anticoagulant use in Japanese patients with atrial fibrillation : insights from the Rivaroxaban Postmarketing Surveillance Registry. J Stroke Cerebrovasc Dis 23 : 2520-2526, 2014.
PubMed
12) Yamashita Y, Uozumi R, Hamatani Y et al : Current Status and Outcomes of Direct Oral Anticoagulant Use in Real-World Atrial Fibrillation Patients- Fushimi AF Registry. Circ J 81 : 1278-1285, 2017.
PubMed
13) Okumura Y, Yokoyama K, Matsumoto N et al : Current use of direct oral anticoagulants for atrial fibrillation in Japan : Findings from the SAKURA AF Registry. J Arrhythm 33 : 289-296, 2017.
PubMed
14) Okumura K, Komatsu T, Yamashita T et al : Time in the therapeutic range during warfarin therapy in Japanese patients with non-valvular atrial fibrillation. -A multicenter study of its status and infuential factors-. Circ J 75 : 2087-2094, 2011.
PubMed
15) J-Rhythm Registry Investigators : Determinants of warfarin use and international normalized ratio levels in atrial fibrillation patients in Japan. -Subanalysis of the J-RHYTHM Registry-. Circ J 75 : 2357-2362, 2011.
 
16) Razouki Z, Ozonoff A, Zhao S et al : Improving quality measurement for anticoagulation : adding international normalized ratio variability to percent time in therapeutic range. Circ Cardiovasc Qual Outcomes 7 : 664-669, 2014.
PubMed
17) Numao Y, Suzuki S, Arita T et al : Predictors of International Normalized Ratio Variability in Patients With Atrial Fibrillation Under Warfarin Therapy. Circ J 82 : 39-45, 2017.
PubMed
18) Gibson CM, Mehran R, Bode C et al : Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. N Engl J Med 375 : 2423-2434, 2016.
PubMed
19) Cannon CP, Bhatt DL, Oldgren J et al : Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation. N Engl J Med 377 : 1513-1524, 2017.
PubMed
20) Katoh H, Nozue T, Asada T et al : Frequency and predictors of bleeding complications associated with anti-coagulant therapy using dabigatran in Japanese patients with atrial fibrillation. Am J Cardiovasc Dis 4 : 70-78, 2014.
PubMed
21) Westenbrink BD, Alings M, Connolly SJ et al : Anemia predicts thromboembolic events, bleeding complications and mortality in patients with atrial fibrillation : insights from the RE-LY trial. J Thromb Haemost 13 : 699-707, 2015.
 
22) Westenbrink BD, Alings M, Granger CB et al : Anemia is associated with bleeding and mortality, but not stroke, in patients with atrial fibrillation : Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Am Heart J 185 : 140-149, 2017.
 
23) Samuelson BT, Cuker A, Siegal DM et al : Laboratory Assessment of the Anticoagulant Activity of Direct Oral Anticoagulants : A Systematic Review. Chest 151 : 127-138, 2017.
PubMed
24) Suzuki S, Otsuka T, Sagara K et al : ABO Blood Type and Response of Activated Partial Thromboplastin Time to Dabigatran in Nonvalvular Atrial Fibrillation Patients. Circ J 79 : 2274-2277, 2015.
PubMed
25) Suzuki S, Yamashita T, Kasai H et al : Response of prothrombin time to rivaroxaban in Japanese patients with non-valvular atrial fibrillation : Characteristics of 5 representative reagents in Japan (CVI ARO 1). Thromb Res 150 : 73-75, 2017.
PubMed
P.440 掲載の参考文献
1) Kirchhof P, Kirchhof P, Benussi S, Kotecha D et al : 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 37 : 2893-2962, 2016.
PubMed
2) January CT, Wann LS, Alpert JS et al : 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation : a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 64 : e1-76, 2014.
 
3) 日本循環器学会 : 心房細動治療 (薬物) ガイドライン (2013年改訂版), 循環器病の診断と治療に関するガイドライン (2012年度合同研究班報告), 日本循環器学会ホームページ (http://www.j-circ.or.jp/guideline/)
 
4) 日本循環器学会 : 不整脈薬物治療に関するガイドライン (2009年改訂版), 循環器病の診断と治療に関するガイドライン (2008年度合同研究班報告), 日本循環器学会ホームページ (http://www.j-circ.or.jp/guideline/)
 
5) 池田隆徳 : 薬剤編 : 抗不整脈薬 (Naチャネル遮断薬・Kチャネル遮断薬). 池田隆徳編, 循環器治療薬の選び方・使い方-症例でわかる薬物療法のポイントと根拠, pp.58-67, 羊土社, 東京, 2009.
 
6) 池田隆徳 : 循環器疾患の薬物療法のポイント : 不整脈. 池田隆徳, 辻野健編, ガイドラインに準じた循環器治療薬ファーストブック, pp.88-104, 南江堂, 東京, 2010.
 
7) Iguchi Y, Kimura K, Aoki J et al : Prevalence of atrial fibrillation in community-dwelling Japanese aged 40 years or older in Japan : analysis of 41,436 non-employee residents in Kurashiki-city. Circ J 72 : 909-913, 2008.
PubMed
8) Inoue H, Fujiki A, Origasa H et al : Prevalence of atrial fibrillation in the general population of Japan : an analysis based on periodic health examination. Int J Cardiol 137 : 102-107, 2009.
PubMed
9) Miyakoshi M, Ikeda T, Miwa Y et al : Quantitative assessment of cibenzoline treatment for vagally mediated paroxysmal atrial fibrillation using frequency-domain heart rate variability analysis. J Cardiol 54 : 86-92, 2009.
PubMed
10) Ishiguro H, Ikeda T, Abe A et al : Antiarrhythmic Effect of Bisoprolol, a Highly Selective β1 Blocker in Patients with Paroxysmal Atrial Fibrillation. Int Heart J 49 : 281-293, 2008.
 
11) Alboni P, Botto GL, Baldi N et al : Outpatient treatment of recent-onset atrial fibrillation with the "pill-in-the-pocket" approach. N Engl J Med 351 : 2384-2391, 2004.
PubMed
12) Al-Khatib SM, Stevenson WG, Ackerman MJ et al : 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death : Executive summary : A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation 138 : e210-e271, 2018.
 
13) Priori SG, Blomstrom-Lundqvist C, Mazzanti A et al : 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death : The task force for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death of the European Society of Cardiology (ESC). Eur Heart J 36 : 2793-2867, 2015.
 
14) 日本循環器学会 : 心臓突然死の予知と予防法のガイドライン (2010年改訂版), 循環器病の診断と治療に関するガイドライン (2009年度合同研究班報告), 日本循環器学会ホームページ (http://www.j-circ.or.jp/guideline/)
 
15) Kato T, Ogawa S, Yamaguchi I et al : Efficacy and safety of intravenous amiodarone infusion in Japanese patients with hemodynamically compromised ventricular tachycardia of ventricular fibrillation. J Arrhythmia 23 : 131-139, 2007.
 
16) Yusu S, Ikeda T, Mera H et al : Effects of intravenous nifekalant as a lifesaving drug for severe ventricular tachyarrhythmias complicating acute coronary syndrome. Circ J 73 : 2021-2028, 2009.
PubMed
17) Miwa Y, Ikeda T, Mera H et al : Effects of landiolol, an ultra-short-acting β1-selective blocker, on electrical storm refractory to class III antiarrhythmic drugs. Circ J 74 : 856-863, 2010.
 
P.449 掲載の参考文献
1) Simonneau G, Montani D, Celermajer DS et al : Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J, 2018. pii : 1801913. doi : 0.1183/13993003.01913-2018.
 
2) Galie N, Humbert M, Vachiery JL et al : 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension : The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS) : Endorsed by : Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 37 (1) : 67-119, 2016.
 
3) 日本高血圧学会高血圧治療ガイドライン作成委員会編 : 高血圧治療ガイドラン 2014 (JSH2014), ライフサイエンス出版, 東京, 2014.
 
4) Ogawa A, Ejiri K, Matsubara H : Long-term patient survival with idiopathic/heritable pulmonary arterial hypertension treated at a single center in Japan. Life Sci 118 (2) : 414-419, 2014.
 
5) Rubin LJ, Badesch DB, Fleming TR et al : Long-term treatment with sildenafil citrate in pulmonary arterial hypertension : the SUPER-2 study. Chest 140 (5) : 1274-1283, 2011.
PubMed
6) Pulido T, Adzerikho I, Channick RN et al : Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 369 (9) : 809-818, 2013.
PubMed
7) Sitbon O1, Channick R, Chin KM et al : Selexipag for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med 373 (26) : 2522-2533, 2015.
 
8) Galie N, Barbera JA, Frost AE et al : Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. N Engl J Med 373 (9) : 834-844, 2015.
PubMed
9) Tokunaga N, Ogawa A, Ito H et al : Rapid and high-dose titration of epoprostenol improves pulmonary hemodynamics and clinical outcomes in patients with idiopathic and heritable pulmonary arterial hypertension. J Cardiol 68 (6) : 542-547, 2016.
PubMed
10) Hoeper MM, Kramer T, Pan Z et al : Mortality in pulmonary arterial hypertension : prediction by the 2015 European pulmonary hypertension guidelines risk stratification model. Eur Respir J 50 (2), 2017.
PubMed
P.460 掲載の参考文献
1) Patel R, Sweeting MJ, Powell JT et al : Endovascular versus open repair of abdominal aortic aneurysm in 15-years' follow-up of the UK endovascular aneurysm repair trial 1 (EVAR trial 1) : a randomised controlled trial. Lancet 388 : 2366-2374, 2016.
PubMed
2) Natsume K, Shiiya N, Takehara Y et al : Characterizing saccular aortic arch aneurysms from the geometry-flow dynamics relationship. J Thorac Cardiovasc Surg 153 : 1413-1420 e1411, 2017.
 
3) Nienaber CA, Kische S, Rousseau H et al : Endovascular repair of type B aortic dissection : long-term results of the randomized investigation of stent grafts in aortic dissection trial. Circ Cardiovasc Interv 6 : 407-416, 2013.
PubMed
4) Desai ND, Gottret JP, Szeto WY et al : Impact of timing on major complications after thoracic endovascular aortic repair for acute type B aortic dissection. J Thorac Cardiovasc Surg 149 : S151-156, 2015.
PubMed
5) Loeys BL, Dietz HC, Braverman AC et al : The revised Ghent nosology for the Marfan syndrome. J Med Genet 47 : 476-485, 2010.
PubMed
6) Milleron O, Arnoult F, Ropers J et al : Marfan Sartan : a randomized, double-blind, placebo-controlled trial. Eur Heart J 36 : 2160-2166, 2015.
 
7) Mullen MJ, Flather MD, Jin XY et al : A prospective, randomized, placebo-controlled, double-blind, multicenter study of the effects of irbesartan on aortic dilatation in Marfan syndrome (AIMS trial) : study protocol. Trials 14 : 408, 2013.
PubMed
8) Powell JT, Sweeting MJ, Ulug P et al : Meta-analysis of individual-patient data from EVAR-1, DREAM, OVER and ACE trials comparing outcomes of endovascular or open repair for abdominal aortic aneurysm over 5 years. Br J Surg 104 : 166-178, 2017.
PubMed
9) Sweeting MJ, Patel R, Powell JT et al : Endovascular Repair of Abdominal Aortic Aneurysm in Patients Physically Ineligible for Open Repair : Very Long-term Follow-up in the EVAR-2 Randomized Controlled Trial. Ann Surg 266 : 713-719, 2017.
PubMed
10) Cao P, De Rango P, Verzini F et al : Comparison of surveillance versus aortic endografting for small aneurysm repair (CAESAR) : results from a randomised trial. Eur J Vasc Endovasc Surg 41 : 13-25, 2011.
PubMed
11) Eisenstein EL, Davidson-Ray L, Edwards R et al : Economic analysis of endovascular repair versus surveillance for patients with small abdominal aortic aneurysms. J Vasc Surg 58 : 302-310, 2013.
PubMed
12) Ali MM, Flahive J, Schanzer A et al : In patients stratified by preoperative risk, endovascular repair of ruptured abdominal aortic aneurysms has a lower in-hospital mortality and morbidity than open repair. J Vasc Surg 61 : 1399-1407, 2015.
 
13) Badger S, Forster R, Blair PH et al : Endovascular treatment for ruptured abdominal aortic aneurysm. Cochrane Database Syst Rev 5 : CD005261, 2017.
PubMed
14) Cheng D, Martin J, Shennib H et al : Endovascular aortic repair versus open surgical repair for descending thoracic aortic disease a systematic review and meta-analysis of comparative studies. J Am Coll Cardiol 55 : 986-1001, 2010.
PubMed
15) Walsh SR, Tang TY, Sadat U et al : Endovascular stenting versus open surgery for thoracic aortic disease : systematic review and meta-analysis of perioperative results. J Vasc Surg 47 : 1094-1098, 2008.
PubMed
16) Ullery BW, Wang GJ, Low D et al : Neurological complications of thoracic endovascular aortic repair. Semin Cardiothorac Vasc Anesth 15 : 123-140, 2011.
PubMed
17) Buth J, Harris PL, Hobo R et al : Neurologic complications associated with endovascular repair of thoracic aortic pathology : Incidence and risk factors. a study from the European Collaborators on Stent /Graft Techniques for Aortic Aneurysm Repair (EUROSTAR) registry. J Vasc Surg 46 : 1103-1110, discussion 1110-1101, 2007.
 
18) Tang GL, Tehrani HY, Usman A et al : Reduced mortality, paraplegia, and stroke with stent graft repair of blunt aortic transections : a modern meta-analysis. J Vasc Surg 47 : 671-675, 2008.
PubMed
19) Xenos ES, Abedi NN, Davenport DL et al : Meta-analysis of endovascular vs open repair for traumatic descending thoracic aortic rupture. J Vasc Surg 48 : 1343-1351, 2008.
PubMed
20) Canaud L, Marty-Ane C, Ziza V et al : Minimum 10-year follow-up of endovascular repair for acute traumatic transection of the thoracic aorta. J Thorac Cardiovasc Surg 149 : 825-829, 2015.
PubMed
21) Okita Y, Miyata H, Motomura N et al : A study of brain protection during total arch replacement comparing antegrade cerebral perfusion versus hypothermic circulatory arrest, with or without retrograde cerebral perfusion : analysis based on the Japan Adult Cardiovascular Surgery Database. J Thorac Cardiovasc Surg 149 : S65-73, 2015.
PubMed
22) Shiiya N : Aortic arch replacement for degenerative aneurysms : advances during the last decade. Gen Thorac Cardiovasc Surg 61 : 191-196, 2013.
PubMed
23) Katayama A, Uchida N, Katayama K et al : The frozen elephant trunk technique for acute type A aortic dissection : results from 15 years of experiencedagger. Eur J Cardiothorac Surg 47 : 355-360, discussion 360, 2015.
PubMed
24) Trimarchi S, Nienaber CA, Rampoldi V et al : Role and results of surgery in acute type B aortic dissection : insights from the International Registry of Acute Aortic Dissection (IRAD). Circulation 114 : I357-364, 2006.
PubMed
25) White RA, Miller DC, Criado FJ et al : Report on the results of thoracic endovascular aortic repair for acute, complicated, type B aortic dissection at 30 days and 1 year from a multidisciplinary subcommittee of the Society for Vascular Surgery Outcomes Committee. J Vasc Surg 53 : 1082-1090, 2011.
 
26) Etz CD, Zoli S, Mueller CS et al : Staged repair significantly reduces paraplegia rate after extensive thoracoabdominal aortic aneurysm repair. J Thorac Cardiovasc Surg 139 : 1464-1472, 2010.
PubMed
27) Greenberg R, Eagleton M, Mastracci T : Branched endografts for thoracoabdominal aneurysms. J Thorac Cardiovasc Surg 140 : S171-178, 2010.
PubMed
28) Ma T, Dong ZH, Fu WG et al : Incidence and risk factors for retrograde type A dissection and stent graft-induced new entry after thoracic endovascular aortic repair. J Vasc Surg 67 : 1026-1033 e1022, 2018.
 
29) Flores J, Kunihara T, Shiiya N et al : Extensive deployment of the stented elephant trunk is associated with an increased risk of spinal cord injury. J Thorac Cardiovasc Surg 131 : 336-342, 2006.
PubMed
30) Usui A, Fujimoto K, Ishiguchi T et al : Cerebrospinal dysfunction after endovascular stent-grafting via a median sternotomy : the frozen elephant trunk procedure. Ann Thorac Surg 74 : S1821-1824, discussion S1825-1832, 2002.
 
31) Katayama K, Uchida N, Katayama A et al : Multiple factors predict the risk of spinal cord injury after the frozen elephant trunk technique for extended thoracic aortic disease. Eur J Cardiothorac Surg 47 : 616-620, 2015.
PubMed
32) David TE, David CM, Feindel CM et al : Reimplantation of the aortic valve at 20 years. J Thorac Cardiovasc Surg 153 : 232-238, 2017.
PubMed
P.467 掲載の参考文献
1) 多田裕輔, 高木淳彦, 佐藤紀他 : 小腸虚血性障害-特に慢性 腹部内臓動脈閉塞症, 腹部アンギーナについて. 外科診療 29 : 1711-1721, 1987.
 
2) 上山武史 : 胸郭出口症候群. 三島好雄, 稲垣義明編, 臨床脈管学 (第1版), pp.257-265, 文光堂, 東京, 1992.
 
3) 草場昭 : バージャー病診断基準. 厚生省特定疾患系統的脈管障害調査研究班編, 治療指針検討小委員会報告1989年度研究報告書, pp.14-16, 1989.
 
4) 稲田潔, 廣瀬光男 : 振動病. 末梢血管の疾患 (第1版), pp.384-397, 金原出版, 東京, 1987.
 
5) Miura T, Soga Y, Doijiri T et al : Prevalence and clinical outcome of polyvascular atherosclerotic disease in patients undergoing coronary intervention. Circ J 77 : 89-95, 2013
PubMed
6) 重松邦広 : 【peripheral arterial disease (PAD) に対する新しい戦略】PAD 原疾患の変遷とその理由. Heart View 18 : 590-595, 2014.
 
7) Usui T, Ninomiya T, Nagata M et al : Albuminuria as a risk factor for peripheral arterial disease in a general population : the Hisayama study. J Atheroscler Thromb 18 : 705-712, 2011.
 
8) Ohnishi H, Sawayama Y, Furusyo N et al : Risk factors for and the prevalence of peripheral arterial disease and its relationship to carotid atherosclerosis : the Kyushu and Okinawa Population Study (KOPS). J Atheroscler Thromb 17 : 751-758, 2010.
 
9) Fujiwara T, Saitoh S, Takagi S et al : Prevalence of asymptomatic arteriosclerosis obliterans and its relationship with risk factors in inhabitants of rural communities in Japan : Tanno-Sobetsu study. Atherosclerosis 177 : 83-88, 2004.
PubMed
10) Ishida A, Miyagi M, Kinjo K et al : Age- and sex-related effects on ankle-brachial index in a screened cohort of Japanese : the Okinawa Peripheral Arterial Disease Study (OPADS). Eur J Prev Cardiol 21 : 712-718, 2012.
 
11) Hozawa A, Ohmori K, Kuriyama S et al : C-reactive protein and peripheral artery disease among Japanese elderly : the Tsurugaya Project. Hypertens Res 27 : 955-961, 2004.
PubMed
12) Norgren L, Hiatt WR, Dormandy JA et al : Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg 45 (Suppl S) : S5-S67, 2007.
 
13) Watson L, Ellis B, Leng GC : Exercise for intermittent claudication. Cochrane Database Syst Rev CD000990, 2008.
PubMed
14) Dormandy JA, Rutherford RB : Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Consensus (TASC). J Vasc Surg 31 (1 Pt 2) : S1-S296, 2000.
 
15) Dawson DL, Cutler BS, Meissner MH et al : Cilostazol has beneficial effects in treatment of intermittent claudication : results from a multicenter, randomized, prospective, double-blind trial. Circulation 98 : 678-686, 1998.
PubMed
16) Norgren L, Jawien A, Matyas L et al : Sarpogrelate, a 5-HT2A receptor antagonist in intermittent claudication. A phase II European study. Vasc Med 11 : 75-83, 2006.
PubMed
17) Miura T, Soga Y, Miyashita Y et al : Five-year prognosis after endovascular therapy in claudicant patients with iliofemoral artery disease. J Endovasc Ther 21 (3) : 381-388, 2014.
 
18) Hirsch AT, Haskal ZJ, Hertzer NR et al : ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic) : a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease) : endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation ; National Heart, Lung, and Blood Institute : Society for Vascular Nursing ; TransAtlantic Inter-Society Consensus ; and Vascular Disease Foundation. Circulation 113 : e463-e654, 2006.
 
19) Conte MS, Pomposelli FB, Clair DG et al : Society for Vascular Surgery practice guidelines for atherosclerotic occlusive disease of the lower extremities : management of asymptomatic disease and claudication. J Vasc Surg 61 (3 Suppl) : 2S-41S, 2015.
 
20) Soga Y, Iida O, Hirano K et al : Mid-term clinical outcome and predictors of vessel patency after femoropopliteal stenting with self-expandable nitinol stent. J Vasc Surg 52 : 608-615, 2010.
 
21) Miura T, Miyashita Y, Soga Y et al : Drug-Eluting Versus Bare-Metal Stent Implantation With or Without Cilostazol in the Treatment of the Superficial Femoral Artery. Circ Cardiovasc Interv 11 (8) : e006564, 2018.
PubMed
22) Iida O, Yokoi H, Soga Y et al : Cilostazol reduces angiographic restenosis after endovascular therapy for femoropopliteal lesions in the sufficient treatment of peripheral intervention by cilostazol study. Circulation 127 : 2307-2315, 2013.
PubMed
23) Tepe G, Laird J, Schneider P et al : Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease : 12-month results from the IN. PACT SFA randomized trial. Circulation 131 (5) : 495-502, 2015.
PubMed
24) Ohki T, Kichikawa K, Yokoi H et al : Outcomes of the Japanese multicenter Viabahn trial of endovascular stent grafting for superficial femoral artery lesions. J Vasc Surg 66 (1) : 130-142, 2017.
PubMed
25) Adam DJ, Beard JD, Cleveland T et al : Bypass versus angioplasty in severe ischaemia of the leg (BASIL) : multicentre, randomized controlled trial. Lancet 366 : 1925-1934, 2005.
PubMed

【研究】

P.476 掲載の参考文献
1) 本田泰斗 : 薬局における感染対策. 田中良子, 木村健 (編), 調剤と情報, 株式会社じほう, 東京, pp.12-16, 2015.
 
2) Boyce JM, Pittet D et al : Guidelines for Hand Hygiene in Health-Care Settings. MMWR Recomm Rep 51 (RR16) : 1-45, 2002.
 
3) 寺沢匡史, 森本一平, 上地隆史他 : 院外薬局における感染対策に関する意識調査 (第2報) ～インフルエンザ (H1N1) 2009 の流行による意識の変化～. 日本環境感染学誌 27 (1) : 57-62, 2012.
 
4) 国立医薬品食品衛生研究所 : 平成27年度ノロウイルスの不活化条件に関する調査, 2015.
 
5) MacIntyre CR, Cauchemez S, Dwyer DE et al : Face mask use and control of respiratory virus transmission in households. Emerg Infect Dis 15 (2) : 233-241. 2009.
PubMed
6) 瀧澤毅 : マスク着用にインフルエンザ予防のエビデンスはあるか? . 千葉科学大学 3 (3) : 149-160, 2010.
 
7) 国立感染症研究所 : 過去10年間との比較, RSウイルス感染症. https://www.niid.go.jp/niid/ja/10/2096-weeklygraph/7904-21rsv-2.html〔2019年2月3日閲覧〕
 
8) 東京都薬剤師会 : 使用済み注射針回収事業. http://www.toyaku.or.jp/contribution/community/collection.html〔2019年2月1閲覧〕
 
9) 田山剛崇 : 保険薬局における感染性医療廃棄物の取り扱いと針刺し曝露の現状. Jpn J Pharm Health Care Sci Notes 36 (12) : 887-892, 2010.
 
10) 厚生労働省医政局 : 検体測定室に関するガイドライン. 平成26年4月版. https://www.mhlw.go.jp/file/06-Seisakujouhou-10800000-Iseikyoku/0000098574.pdf〔2019年2月1閲覧〕
 

【臨床研究】

P.490 掲載の参考文献
1) ロナセン(R) 錠2mg, 同錠4mg, 同錠8mg, 同散2%医薬品インタビューフォーム 2018年4月改訂 (第11版)
 
2) 後発医薬品の生物学的同等性試験ガイドラインについて (平成9 年12 月22 日付医薬審第487号)
 
3) 後発医薬品の生物学的同等性試験ガイドライン等の一部改正について (平成24年2月29日薬食審査発0229 第10号)
 
4) 医薬品の臨床試験の実施の基準に関する省令 (平成9年3月27日付厚生省令第28号)
 
5) 医薬品の臨床試験の実施の基準に関する省令の一部を改正する省令 (平成28年1月22日付厚生労働省令第9号), 医薬品の臨床試験の実施の基準に関する省令の一部を改正する省令の施行について (平成28年1月22日付薬生発0122 第2号)
 
6) ロナセン(R) 錠2mg, 同錠4mg, 同錠8mg, 同散2%添付文書2018年4月改訂 (第12版)
 
P.504 掲載の参考文献
1) ロナセン(R) 錠2mg, 同錠4mg, 同錠8mg, 同散2%医薬品インタビューフォーム2018年4月改訂 (第11版)
 
2) 後発医薬品の生物学的同等性試験ガイドラインについて (平成9年12月22日付医薬審第487号)
 
3) 後発医薬品の生物学的同等性試験ガイドライン等の一部改正について (平成24年2月29日薬食審査発0229 第10号)
 
4) 医薬品の臨床試験の実施の基準に関する省令 (平成9年3月27日付厚生省令第28号)
 
5) 医薬品の臨床試験の実施の基準に関する省令の一部を改正する省令 (平成28 年1月22日付厚生労働省令第9号), 医薬品の臨床試験の実施の基準に関する省令の一部を改正する省令の施行について (平成28年1月22日付薬生発0122 第2号)
 
6) ロナセン(R) 錠2mg, 同錠4mg, 同錠8mg, 同散2%添付文書2018年4月改訂 (第12版)
 

【Diagnosis】

P.509 掲載の参考文献
1) 玉井悠子, 網嶋千里, 石井清他 : インフルエンザ迅速診断キットラピッドテスタ(R) FLU・NEOの検出感度と操作性に関する検討. 機器-試薬 35 (5) : 771-776, 2012.
 
2) 山崎雅彦, 市川雅彦, 安倍隆他 : インフルエンザウイルス迅速診断システムラピッドテスタ(R) リーダーの臨床評価. 医学と薬学 75 (11) : 1461-1470, 2018.
 
P.516 掲載の参考文献
1) 平成29年度・第51回臨床検査精度管理調査結果報告書 [免疫血清検査装置].
 
2) 飯田健一, 狩野吉康, 髭修平, 豊田成司 : 全自動化学発光免疫測定システムARCHITECTによるHBc抗体およびHBs抗体測定の有用性評価. Prog Med 22 : 1037-1046, 2002.
 
3) 米澤仁, 且股志織, 久保麻里子, 渡邉直樹他 : 化学発光酵素免疫測定法を用いた「ルミパルスプレストHBcAb III」の性能評価. JJCLA 38 : 203-206, 2013.
 
P.539 掲載の参考文献
1) 奥村伸生, 戸塚実, 矢冨裕 : 臨床検査法提要 第33版. 金井正光監, pp.554-563, 金原出版, 東京, 2010.
 
2) 黒川清, 春日雅人, 北村聖 : 臨床検査データブック 2013-2014. 高久史麿監 : pp.642-660, 医学書院, 東京, 2013.
 
3) 石黒厚至 : CA19-9 検査編. 臨床検査 59 : 632-637, 2015.
 
P.547 掲載の参考文献
1) Salmon W D, Daughaday W H : A hormonally controlled serum factor which stimulates sulphate incorporation by cartilage in vitro. J Lab Clin Med 49 : 825-826, 1957.
PubMed
2) Daughaday W H, Hall K, Raben M S et al : Somatomedin : proposed designation for sulphation factor. Nature 235 : 107, 1972.
PubMed
3) Jones J I, Clemmons D R : Insulin-like growth factors and their binding proteins : biological actions. Endocr Rev 16 : 3-34, 1995.
PubMed
4) Baxter R C : Changes in the IGF-IGFBP axis in critical illness. Best Pract Res Clin Endocrinol Metab 15 : 421-434, 2001.
PubMed
5) Livingstone C : Insulin-like growth factor-I (IGF-I) and clinical nutrition. Clinical Science 125 : 265-280, 2013.
PubMed
6) Isojima T, Shimatsu A, Yokoya S et al : Standardized centile curves and reference intervals of serum insulin-like growth factor-I (IGF-I) levels in a normal Japanese population using the LMS method. Endocr J 59 : 711, 2012.
 
7) エクルーシス(R) 試薬IGF-1 添付文書 http://www.info.pmda.go.jp/tgo/pack/229AAEZX00124000_A_01_01/
 
8) Ishii H, Shimatsu A, Nishinaga H : et al : Assessment of quality of life on 4-year growth hormone therapy in Japanese patients with adult growth hormone deficiency : A post-marketing, multicenter, observational study. Growth Horm. IGF Res 36 : 36-43, 2017.
 

【Cosmetic】

P.552 掲載の参考文献
1) 前田憲寿 : 皮膚と科学-内と外の境界. 化学と教育 65 (2) : 84-85, 2017.
 
2) 谷井司, 加藤順子他 : 乾燥性皮膚疾患に対するスクワランの有用性, 皮膚刺激性および保湿性についての検討. 皮膚 33 (2) : 155-163, 1991.
 
3) 芋川浩, 今浪愛里 : 精油 (ティートリーとラベンダー) の抗菌効果の検討 その1. 福岡県立大学看護学研究紀要 11 (2) : 63-70, 2014.
 

書評

最近チェックした商品履歴

Loading...